Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
The DOI matches its Crossref record; 144 of the 147 references it cites were found in a registry or an index.
Abstract
Characterization of mice with cell-specific deletion or overexpression of the mineralocorticoid receptor (MR) shed a new light on its role in health and disease. Pathophysiological MR activation contributes to a plethora of deleterious molecular mechanisms in the development of cardiorenal diseases like chronic kidney disease (CKD) and heart failure (HF). Accordingly, the available steroidal MR antagonists (MRAs) spironolactone (first generation MRA) and eplerenone (second generation MRA) have been shown to be effective in reducing cardiovascular (CV) mortality and morbidity in patients with chronic HF and a reduced left ventricular ejection fraction (HFrEF). However, they remain underutilized, in large part owing to the risk inducing severe adverse events including hyperkalemia and worsening of kidney function, particularly when given on top of inhibitors of the renin angiotensin system (RAS) to patients with concomitant kidney dysfunction. Novel, potent, and selective non-steroidal MRAs (third generation) were identified in drug discovery campaigns and a few entered clinical development recently. One of these is finerenone with different physicochemical, pharmacokinetics, and pharmacological properties in comparison with the steroidal MRAs. Available data from five clinical phase II trials with finerenone in more than 2,000 patients with HF and additional CKD and/or diabetes as well as in patients with diabetic kidney disease demonstrated that neither hyperkalemia nor reductions in kidney function were limiting factors to its use. Moreover, finerenone demonstrated a nominally improved outcome compared to eplerenone in a phase IIb trial with 1,066 patients with HFrEF and concomitant type 2 diabetes mellitus (T2DM) and/or CKD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finerenone is a novel, selective, nonsteroidal MR antagonist (MRA) that blocks MR-mediated sodium reabsorption and MR overactivation and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical kidney and cardiovascular disease models.8 , 9”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [9]
In the citing paper
“As a nonsteroidal, selective mineralocorticoid receptor antagonist, finerenone has been shown to have potent anti-inflammatory and antifibrotic effects while reducing the urinary albumin-to-creatinine ratio, which may be related to its benefits in renal outcome and HHF [67–70].”
In the citing paper
“As a nonsteroidal, selective mineralocorticoid receptor antagonist, finerenone has been shown to have potent anti-inflammatory and antifibrotic effects while reducing the urinary albumin-to-creatinine ratio, which may be related to its benefits in renal outcome and HHF [67–70].”
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citation2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationTrends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T. E., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,191
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8807 · Cited by 3,304
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citation
Research works printed but not linked: 5
- Ergueden JK, Kolkhof P, Sandner P, Kuhl A, Stasch JP, Pook E, Schlemmer KH (2005) Fluorenone 1, 4,-dihydropyridin derivatives, WO/2005/087740. Bayer Healthcare AG, Wuppertal
- Kolkhof P, Flamme I, Figueroa-Pérez S, Baerfacker L, Hartmann E, Rinke M, Schäfer S (2006) Cardiac and renal protection by a new mineralocorticoid receptor antagonist in salt-sensitive hypertension [abstract P754]. Eur Heart J 27(Suppl 1):110
- Mulder P, BarreraChimal J, El Moghrabi S, Kolkhof P, Ouvrard-Pascaud A, Jaisser F (2016) Finerenone improves diastolic function in a preclinical model of type2 diabetes mellitus. Eur Heart J 37(Abstract Supplement):829
- Platt D, Pauli H (1972) Studies on organ- and subcellular distribution of [3H]spironolactone in animals [in German]. Arzneimittelforschung 22:1801–1802
- Simpson SA, Tait JF (1953) Memoirs of the Society for Endocrinology, No. 2. The determination of adrenal cortical steroids and their metabolites. Dennis Dobson, Ltd., London, p 9
Cited by
Items 101–180 of 180
The role of aldosterone inhibitors in cardiac ischemia–reperfusion injury
Dragasevic, N., Jakovljevic, V. L., Zivkovic, V. I., Draginic, N. D., Andjic, M. M., Bolevich, S., & Jović, S. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2020-0276 · Cited by 8
“This phenomenon is called ischemia/reperfusion (I/R) injury and occurs in several forms such as reperfusion-induced arrhythmias, microvascular obstruction, myocardial stunning, and reperfusion-induced cardiomyocyte death (Kolkhof et al. 2016; Domenic et al. 2015; Grombein et al. 2015).”
BackgroundBlankenburg, M., Kovesdy, C. P., Fett, A.-K., Griner, R., & Gay, A. (2020) · BMC Nephrology · doi:10.1186/s12882-020-01719-7 · Cited by 9
“Overactivation of the mineralocorticoid receptor (MR) occurs under pathological conditions and contributes to hypertrophy, inflammation, and fibrosis, leading to cardiovascular and renal damage [16, 17].”
BackgroundZhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1623050/v1 · Cited by 7
SGLT2 Inhibitors and Finerenone: A friendly Duo in the Treatment of Diabetic Kidney Disease?
Asirvatham, A. R., Asirvatham, A. J., & Mahadevan, S. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0759 · Cited by 7
“50 Shorter half-life and lack of active metabolites of finerenone significantly reduce the risk of hyperkalemia and can be reversed with brief discontinuation of the drug in rare instances.”
Bozkurt, B., Januzzi, J. L., & Bansal, S. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm38690 · Cited by 8
“…distribution of finerenone was similar between the heart and kidneys (4409 vs 3782 µg-eq/L, respectively) [34], while eplerenone and spironolactone were found to be enriched in the kidneys (kidney:heart tissue distribution ratios: ≥ 6:1 and 3:1 for spironolactone and eplerenone, respectively) [26].”
Finerenone: A Novel Mineralocorticoid Receptor Antagonist for Cardiorenal Protection in CKD and T2DM
Long, A., & Salvo, M. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280211059577 · Cited by 6
Pollard, C. M., Suster, M. S., Cora, N., Carbone, A. M., & Lymperopoulos, A. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i4.220 · Cited by 6
Upadhyay, A., & Haider, L. (2024) · Clinical Diabetes · doi:10.2337/cd24-0036 · Cited by 6
Efficacy and safety of finerenone in obesity-related glomerulopathy
Qiu, D., Liu, J., Chen, R.-H., Zhang, F., An, Y., & Jiang, S. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf157 · Cited by 6
“This improvement is attributed to its greater selectivity and affinity for the receptor [7 , 8 ].”
Wright, W. L., Urquhart, S., & Brunton, S. (2023) · Journal of Primary Care & Community Health · doi:10.1177/21501319231153599 · Cited by 7
Quintero, G. S. A., Lima, A. E., Roig, P., Meyer, M., de Kloet, E. R., Nicola, A. F. D., & Garay, L. I. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106461 · Cited by 8
Imran, S. J., Kini, S. G., Kumar, V. P., Sonawane, B. S., Chaudhari, J., & Warde, S. (2023) · Research Square · doi:10.21203/rs.3.rs-2984018/v1 · Cited by 6
Ramadan, M. M., Alajmi, S., Aldouseri, J., Alajmi, M., Tello, E., Mahdi, A.-M. O., Aladwani, A. J., AlAyyaf, A. E., Mahdi, O., & Elmahal, M. (2025) · Cureus · doi:10.7759/cureus.87706 · Cited by 8
“Mechanistically, Finerenone induces distinct conformational changes in MR by binding to a unique hydrophobic pocket, preferentially inhibiting proinflammatory (e.g., NF-κ B) and profibrotic (e.g., TGF-β ) signaling pathways more effectively than steroidal MRAs [26].”
Saito, R., & Nakada, T. (2024) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101019 · Cited by 6
Jiang, W., Wang, M., Yang, W., Yao, X., & Li, N. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04756-z · Cited by 4
“Influential authors such as Pitt Bertram, Zannad Faiez, and Rossignol Pat-rick have played pivotal roles in advancing the field, particularly in landmark studies on MRAs and cardiorenal syndromes [24, 27].”
Finerenone’s Promise in Heart Failure and Kidney Disease
Shokri, K., Mohammadi, A., Karimian, A., Adeel, M. Y., Mozaffari, M. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000958 · Cited by 5
Almas, T., Shelig, M., Al-Hindawi, A., Bansal, K., Akbar, A., Qureshi, A. N., Ismayl, M., Reed, J. A., Burahmah, J., Alhamlan, A. W., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag014 · Cited by 5
Geraci, G., Sinatra, N., Paternò, V., Calabrese, V., Cassataro, G., Cuttone, G., Geraci, C., Esposito, R., Mancusi, C., Pucci, G., et al. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07890-7 · Cited by 3
“…diabetic kidney disease (DKD) have demonstrated that finerenone suppresses nuclear factor-κB (NF-κB) acti - vation, leading to reduced expression of pro-inflammatory cytokines including interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and monocyte chemoattractant protein-1 (MCP-1) [28, 29].”
Jelwan, Y. A., Cao, T., Yao, Z., Burka, S., Erhabor, J., Berning, P., Dzaye, O. D. A., & Blaha, M. J. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.046837 · Cited by 4
Inflammation in Diabetic Kidney Disease: Focus on New Therapeutic Considerations
Leehey, D. J., & Zhang, X. (2023) · Medical Research Archives · doi:10.18103/mra.v11i2.3614 · Cited by 3
Corticosteroid Receptors in Cardiac Health and Disease
Ivy, J. R., Gray, G. A., Holmes, M. C., Denvir, M. A., & Chapman, K. E. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_6 · Cited by 3
Finerenone in Patients with Nondiabetic Chronic Kidney Disease—A Retrospective Study
Albakr, R. B., Al‐Rowaie, F., Sandokji, I. A., Alhadlg, Y. A., Almatham, K., & Albacker, A. B. (2025) · Biomedicines · doi:10.3390/biomedicines13102519 · Cited by 3
“It is favored over earlier medications like spironolactone and eplerenone due to its lower propensity for cardiorenal complications and hyperkalemia [4,5].”
Liu, Y., Zhang, Z., Zhou, H., Yan, Y., Zhou, M., Wang, C., Gao, M., Tao, J., Bao, M., Yang, T., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1686480 · Cited by 2
Interplay between caveolin-1 and mineralocorticoid receptor in cardiometabolic disease
Czarzasta, K., & Pojoga, L. H. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0341 · Cited by 3
Jin, Y., Fan, M., Zheng, X., & Zhu, S. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2392006 · Cited by 4
“Hyperkalemia was the most frequently ADR in two major clinical studies [11,33], attributable to the potas-sium-sparing effect of MRAs [34–36].”
Finerenone in type 1 diabetes and chronic kidney disease: short-term efficacy and safety insights
Qiu, D., Wang, J., Li, A., Zhang, W., Du, X., Wang, G., & Jiang, S. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04773-y · Cited by 2
“As a non-steroidal selective mineralocorticoid receptor antagonist (MRA), finerenone demonstrates enhanced anti-inflammatory and anti-fibrotic effects compared to traditional steroidal MRAs, with a more favorable safety profile including hyperkalemia and kidney function deterioration [7, 8].”
Desimine, V. L., Ghandour, J., Cora, N., Pollard, C. M., Valiente, R., Ferraino, K. E., Pereyra, J. M., Noa, D. P., Duarte, Y., Martinez, Y., et al. (2020) · Preprints.org · doi:10.20944/preprints202009.0374.v1 · Cited by 1
Advances in the Development of Non-steroidal Mineralocorticoid-receptor Antagonists
Pérez-Gordillo, F. L., de Vega, M. J. P., Gerona‐Navarro, G., Rodríguez, Y., de la Rosa, D. Á., González‐Muñiz, R., & Martín‐Martinez, M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88417 · Cited by 2
“The benefits of MR antagonists in patients with heart failure resulted in the approval of their use to treat this condition [10].”
BackgroundMechanistic Understanding of Finerenone in Hypertension Management: A Narrative Review
Prasad, M., Rashid, S. A., YASHVANTHAN, V. R., Prakash, B. M., & Priya, M. D. L. (2025) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/3217 · Cited by 1
Therapeutic strategy for diabetic patients with cardiovascular-kidney-metabolic syndrome
Huang, J., Zuo, P.-Y., Zhang, C., & Yan, J. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf180 · Cited by 1
Nuclear receptors as therapeutic targets in metabolic and cardiovascular disorders
Li, F., Chen, Q., Dai, Y., & Lu, L. (2025) · iScience · doi:10.1016/j.isci.2025.114042 · Cited by 1
Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease
Mottl, A. K., Khunti, K., & Mathieu, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70587 · Cited by 2
“1,3,19 In the kidneys, MR overactivation may induce glomerulo-sclerosis, interstitial fibrosis, proteinuria, and a decline in glomerular filtration rate, eventually leading to CKD. 8,20 Similarly, CKD associated with diabetes, a major cause of end-stage kidney disease globally, may arise from…”
Pilarski, B., Florek, S., Suchodolski, A., Szulik, M., & Pudło, R. (2026) · Brain Sciences · doi:10.3390/brainsci16050452 · Cited by 1
“Although MRAs, such as spironolactone and eplerenone, effectively reduce mortality, their use is limited due to the risk of hyperkalemia and deterioration of renal function, particularly when combined with RAAS inhibitors [52].”
Rossi, G. P. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001686 · Cited by 1
“A further member of the family that has been most recently discovered is finerenone, a dihydropyridine derivative, that is being developed for the treatment of heart failure [6], and diabetic nephropathy [7].”
BackgroundAkyüz, C., Uzun, O., Sunamak, O., Velioğlu‐Öğünç, A., & Çetınel, Ş. (2018) · Journal of Research in Pharmacy · doi:10.12991/jrp.2018.83 · Cited by 1
“Spironolactone, a mineralocorticoid receptor antagonist, has been shown to reduce morbidity and mortality in patients with heart failure [6].”
BackgroundLanthier, L., Plourde, M.-É., & Cauchon, M. (2021) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.12.013 · Cited by 1
Focus on Finerenone, a Non-Steroidal MRA in Diabetic Kidney Disease. What Physicians Should Know?
Chakraborty, D. S., Choudhury, S., & Lahiry, S. (2022) · Medicina Moderna - Modern Medicine · doi:10.31689/rmm.2021.29.1.25 · Cited by 2
Zhang, F., & Jiang, X. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001800 · Cited by 1
Advances in the Development of Non-steroidal Mineralocorticoidreceptor Antagonists
Pérez-Gordillo, F. L., González-Muñiz;, ;. G. G.-N. Y. R. D. A. D. L. R. R., & Martín‐Martinez, M. (2019) · doi:10.25419/rcsi.10786676.v1 · Cited by 1
Hermidorff, M. M., de Assis, L. V. M., Rodrigues, J. A., Soares, L. L., de Andrade, M. H. G., Natali, A. J., & Isoldi, M. C. (2019) · Heart and Vessels · doi:10.1007/s00380-019-01542-7 · Cited by 1
Tailoring the management of hypertension to comorbidities
Mendoza, M. F., Kachur, S. M., & Lavie, C. J. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000860 · Cited by 1
“hyperkalemia nor further renal dysfunction were noted with the use of finerenone [82,87].”
BackgroundAdministration of finerenone in chronic kidney disease
Sepahi, M. A., Emami, E., Joseph, A., Hassanzadeh, S., & Razavi, M. R. (2022) · Journal of Nephropathology · doi:10.34172/jnp.2022.17355 · Cited by 2
“This study showed that finerenone possesses superior anti-inflammatory and antifibrotic effects in preclinical models compared to other steroidal MRAs (27,28).”
BackgroundZhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1623050/v2 · Cited by 1
Béhar‐Cohen, F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816800-4.00001-2
Pharmacoepidemiology in Cardiorenal Medicine
Tecson, K. M., & Shafiei, S. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-57460-4_24
Rocha, N. A., & McCullough, P. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-57460-4_8
Chakaroun, R. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00705-9
Wu, H., Wen, Y., Huang, J., Zhang, L., & Yang, X. (2021) · Research Square · doi:10.21203/rs.3.rs-962831/v1
Hasani, E., Rroji, M., & Barbullushi, M. (2022) · Albanian Journal of Trauma and Emergency Surgery · doi:10.32391/ajtes.v6i1.263
Aldosterone and Its Cardiovascular Effects
Garg, R., & Adler, G. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-803247-3.00026-x · Cited by 1
Research Progress of Mineralocorticoid Receptor Antagonists on Diabetic Kidney Disease
王, 璇. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.131065
D’Errico, M. M. (2022) · The Journal of AMD · doi:10.36171/jamd22.25.4.5
Chronische Niereninsuffizienz bei Typ-2-Diabetes – die stille Bedrohung einer Multisystemerkrankung
Günes-Altan, M., & Schmieder, R. E. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2318-3452
Cosmo, S. D., Pontremoli, R., Giandalia, A., Manicardi, V., Rocca, A., Nicolucci, A., Rossi, M. C., Lucisano, G., Graziano, G., Bartolo, P. D., et al. (2024) · Journal of Nephrology · doi:10.1007/s40620-024-02171-8
“The new nonsteroidal mineralocorticoid receptor antagonists are more selective, have few active metabolites and a shorter half-life, so they are less burdened by potentially serious side effects such as hyperkalemia, gynecomastia and erectile dysfunction [17].”
Fei, Y., Xie, Z., Luo, Y., Yong, X., Li, N., Huang, R. T., Du, X., Zhu, Y., Lan, D., Yang, Q., et al. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s500384
“19,20 Thus, the development of non-steroidal MRAs is imperative.”
López, J. P., Capote, P. A. C., Pozo, A. H., Guerra, L. C., García, J. L., Olmo, R. F., & Huete, M. J. E. (2025) · Nefrología · doi:10.1016/j.nefro.2025.501359 · Cited by 1
Seo, S., & Sohn, J. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001948
Doumani, G., Theofilis, P., Vordoni, A., Smirloglou, D., & Kalaitzidis, R. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09747-2
Ahire, P. D., Kawale, L. A., & Nade, V. S. (2025) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3427
López, J. P., Capote, P. A. C., Pozo, A. H., Castilla‐Guerra, L., Fernández‐García, J. C., Olmo, R. F., & Huete, M. J. E. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.501359 · Cited by 1
“…en que finerenona sea el único antagonista del receptor mineralocorticoide que haya demostrado reducir la progresio ́ n de la enfermedad renal y el riesgo de desarrollar complicaciones cardiovasculares en los pacientes con DM2 y ERC, además de presentar un menor riesgo de hiperpotasemia 21,46-51 .”
Chronische Niereninsuffizienz bei Typ-2-Diabetes – die stille Bedrohung einer Multisystemerkrankung
Günes-Altan, M., & Schmieder, R. (2025) · Diabetes aktuell · doi:10.1055/a-2624-4700
Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy
Mendoza, J. M., Weir, M. R., Anker, S. D., Filippatos, G. S., Rossing, P. R., Ahlers, C., BRINKER, M. D., Fatoba, S., Horvat-Broecker, A., Rohwedder, K., et al. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000932
Self-citationMineralocorticoid receptor antagonists in internal medicine practice
Arutyunov, G. P., Batyushin, М. М., Вадимовна, В. С., Galyavich, A. S., Koziolova, N. A., Lopatin, Y. M., Nedogoda, S. V., Orlova, Y. A., Салухов, В. В., Tarlovskaya, E. I., et al. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6575
Iwamoto, T., Hidaka, S., Iwamoto, M., & Shibata, H. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109308
Baxdrostat for the treatment of primary aldosteronism: current evidence
Menino, J., Vega, A., Goi, J., & Araujo-Castro, M. (2026) · Endocrine · doi:10.1007/s12020-026-04570-2 · Cited by 1
Lin, W., Huang, T.-S., Chang, H.-H., Chao, J.-Y., Chang, Y.-H., Yang, C., Ou, H., & Lin, W. (2026) · Clinical and Translational Science · doi:10.1111/cts.70509
“One possible explanation is SL's partial MR activity due to its recruitment of MR cofactors, a property not observed with finerenone, a nonsteroidal MRA [28–30].”
Finerenone in heart failure with ejection fraction ≥40%: state of the art and future perspectives
Llàcer, P., Marcos, M. C., Núñez, J. E., Perez-Belmonte, L. M., Pérez-Silvestre, J., Martéles, M. S., & Colet, J. C. (2026) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2026.502520
Pieronne-Deperrois, M. (2022) · theses.fr (ABES) · doi:10.70675/71ef46cfz0230z4862za32aze1072fe4be66
Llàcer, P., Marcos, M. C., Nuñez, J., Perez-Belmonte, L. M., Pérez-Silvestre, J., Marteles, M. S., & Colet, J. C. (2026) · Revista Clínica Española · doi:10.1016/j.rce.2026.502520
Lopatin, Y. M., Tereshchenko, S. N., Arutyunov, G. P., Вадимовна, В. С., Galyavich, A. S., Duplyakov, D. V., Жиров, И. В., Звартау, Н. Э., Irtyuga, O. B., Koziolova, N. A., et al. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-6850
Murtafa, K. M., Khanday, S. S., Srinivasan, R. V., Majeed, M. W., Arumapperuma, H. A., Anilkumar, A., Mohammed, S., Arshad, M. R., Chishti, M. L., & Andrabi, S. (2026) · International Urology and Nephrology · doi:10.1007/s11255-026-05209-x · Cited by 1
Zhang, H., Li, M., & Deng, W. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118201 · Cited by 2
Rico-Fontalvo, J. E., Raad-Sarabia, M., de la Flor, J. C., Polo, V. S., Benavides, J., Clason, E. R., Domínguez, D., Rebutti, G. M., Mancia, C. M., López, R. T., et al. (2026) · Medicina · doi:10.3390/medicina62071317
Wu, J., Lee, K.-W., Huang, S.-C., Chang, H.-Y., & Lin, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1837944
Wu, J.-Y., Lee, K.-W., Huang, S.-C., Chang, H.-Y., & Lin, Y. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-06384-6
Regulation of the Mineralocorticoid Receptor in Physiology and Disease
Young, M. J., Fuller, P. J., Meijer, O. C., Cole, T. J., Kanki, M., Yang, J., Ho, Q. V., Karthigan, N., & Heanue, S. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100156
韩, 昱. (2026) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2026.54263
Diagnostic challenges in primary aldosteronism evaluation and finerenone use
Xu, Y., Song, K., Wu, S., Li, J., & Pan, S. (2026) · Journal of Medical Case Reports · doi:10.1186/s13256-026-06619-2
“Compared with traditional steroidal MRAs, finerenone exhibits higher selectivity for the MR and shows minimal cross-reactivity with the glucocorticoid receptor, androgen receptor, and progesterone receptor; consequently, it is associated with fewer hormone-related adverse effects [9].”
Normuradov, A. U., Zhirov, I., & Tereshchenko, S. (2026) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20262103111
Metadata
- Authors
- Kolkhof, P., Jaisser, F., Kim, S.-Y., Filippatos, G., Nowack, C., & Pitt, B.
- Affiliations
- Bayer (Germany) (DE)
- National and Kapodistrian University of Athens (GR)
- University of Michigan (US)
- Corresponding author
- Kolkhof, Peter
- Venue
- Handbook of Experimental Pharmacology
- Publisher
- Springer International Publishing
- Published
- 2016
- Volume
- 243
- Pages
- 271-305
- ISSN
- 0171-2004 (ISSN-L)
- 1865-0325
- OpenAlex
- W2555239285
- Cited by
- 180
- References
- 147
- Citations by year
- 2026: 22 · 2025: 25 · 2024: 22 · 2023: 23 · 2022: 28 · 2021: 20 · 2020: 16 · 2019: 14 · 2018: 6 · 2017: 3 · 2016: 1
- FWCI
- 33.76
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Handbook of experimental pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- mineralocorticoid receptor antagonists, finerenone, spironolactone, eplerenone, heart failure with reduced ejection fraction, chronic kidney disease, cardiorenal disease, diabetic nephropathy, hyperkalemia, renin-angiotensin system inhibitors, type 2 diabetes, non-steroidal MRAs, drug safety and efficacy
- MeSH terms
- Eplerenone, Mineralocorticoid Receptor Antagonists, Animals, Diabetic Nephropathies, Fibroblasts, Heart Failure, Humans, Macrophages, Muscle, Smooth, Vascular, Naphthyridines, Spironolactone, Stroke Volume, Receptors, Mineralocorticoid, Myocytes, Cardiac, Myocytes, Smooth Muscle, Endothelial Cells, Cardio-Renal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.